Fulgent Genetics (FLGT) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fulgent Genetics (FLGT) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, losing 8.8% versus a loss of 10.9%. Over five years, FLGT leads with a -73.3% price change compared with -95.2% for IMDX. Fulgent Genetics is the larger company by market cap ($572.9 million vs $107.3 million), about 5.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLGT | IMDX |
|---|---|---|
| Share price | $20.82 | $3.28 |
| Market cap | $572.87M | $107.34M |
| 1-day change | +1.22% | -5.20% |
| YTD return | -20.75% | -56.27% |
| 1-year return | -8.80% | -10.87% |
| 5-year return | -73.31% | -95.18% |
| EPS (TTM) | $-2.82 | $-1.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.04 | $8.51 |
| 52-week low | $13.46 | $2.42 |
| Distance from 52-week high | -32.93% | -61.46% |
| Analyst consensus | none | none |
| Avg. price target upside | -8.74% | +151.52% |
| Average volume | 301.04K | 232.87K |
| Shares outstanding | 27.52M | 32.72M |
| Employees | 1,315 | 55 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Fulgent Genetics is about 5.3 times larger than Insight Molecular Diagnostics by market value ($572.87M vs $107.34M).
About Fulgent Genetics
FLGT stock →Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Healthcare · Diagnostics & Research · 1,315 employees
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Healthcare · Diagnostics & Research · 55 employees
FLGT vs IMDX FAQ
Which is bigger, Fulgent Genetics or Insight Molecular Diagnostics?
Fulgent Genetics (FLGT) is larger, with a market capitalization of $572.87M compared with $107.34M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, FLGT or IMDX?
FLGT returned -8.80% over the past 12 months, compared with -10.87% for IMDX (price return, excluding dividends). Past performance does not predict future results.
Are Fulgent Genetics and Insight Molecular Diagnostics in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.